Sevoflurane Represents an Incredible Opportunity and You Know it NOW!
RxElite Holdings, Inc. More on Servoflurane!
You need to know two vital pieces of information:
1. RxElite is one of three distributors in the U.S. for the most widely used inhalable anasthetic in the world — Read the Oppenheimer Reports:
A. June 28, 2007, Oppenheimer Report
B. August 18, 2007, Oppenheimer Report
2. RxElite will be sharing this information widely on Tuesday at a conference.
You know it now!
While RxElite does have a pipeline of products their immediate revenue stream is derived from Sevoflurane.
Sevoflurane is currently the primary product of RxElite. It is the number one inhalation anesthetic agent in the world.
RxElite joins Baxter International and Abbott Labs as the third sevoflurane distributor and the three companies will share sales. RxElite will distribute sevoflurane (Sojourn) for Minard International.
It is expected that inhaled anesthetics will remain the foundation of anesthesia for many years to come as there is no alternative drug class in development and no alternative technologies in development.
As the aging population represents an increasing demand for surgery in the next decades the demand for anesthesia will increase.
Source: RxElite Holdings, Inc.
RxElite Holdings, Inc.
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191 Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
Segue Ventures LLCAbout RxElite Holdings, Inc.: RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.Disclosure: Pentony Enterprises LLC was compensated $18,000.00. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC,9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com.
